A citation-based method for searching scientific literature

Ewelina Kulikowski, Brooke D Rakai, Norman C W Wong. Med Res Rev 2021
Times Cited: 44







List of co-cited articles
440 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Nicola R Harker, Enid Y N Lam, Chun-Wa Chung, Paul Bamborough, Massimo Petretich,[...]. Science 2020
167
38

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
38

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018
242
31

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
27

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Emily J Faivre, Keith F McDaniel, Daniel H Albert, Srinivasa R Mantena, Joshua P Plotnik, Denise Wilcox, Lu Zhang, Mai H Bui, George S Sheppard, Le Wang,[...]. Nature 2020
165
27



Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
202
22

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005
885
22



RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Sarah Picaud, Christopher Wells, Ildiko Felletar, Deborah Brotherton, Sarah Martin, Pavel Savitsky, Beatriz Diez-Dacal, Martin Philpott, Chas Bountra, Hannah Lingard,[...]. Proc Natl Acad Sci U S A 2013
293
20

BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.
Qiming Duan, Sarah McMahon, Priti Anand, Hirsh Shah, Sean Thomas, Hazel T Salunga, Yu Huang, Rongli Zhang, Aarathi Sahadevan, Madeleine E Lemieux,[...]. Sci Transl Med 2017
139
20

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
20


Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation.
Friederike Itzen, Ann Katrin Greifenberg, Christian A Bösken, Matthias Geyer. Nucleic Acids Res 2014
138
18

Drug Discovery Targeting Bromodomain-Containing Protein 4.
Zhiqing Liu, Pingyuan Wang, Haiying Chen, Eric A Wold, Bing Tian, Allan R Brasier, Jia Zhou. J Med Chem 2017
166
18

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
845
18

Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain.
George S Sheppard, Le Wang, Steven D Fidanze, Lisa A Hasvold, Dachun Liu, John K Pratt, Chang H Park, Kenton Longenecker, Wei Qiu, Maricel Torrent,[...]. J Med Chem 2020
53
18

The BET family in immunity and disease.
Nian Wang, Runliu Wu, Daolin Tang, Rui Kang. Signal Transduct Target Ther 2021
52
18

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, Patricia LoRusso, Russell Szmulewitz, Sapna Pradyuman Patel, Primo N Lara, Xiaotian Chen, Beibei Hu, Kevin J Freise,[...]. Clin Cancer Res 2019
78
15

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Laura M Tsujikawa, Li Fu, Shovon Das, Christopher Halliday, Brooke D Rakai, Stephanie C Stotz, Christopher D Sarsons, Dean Gilham, Emily Daze, Sylwia Wasiak,[...]. Clin Epigenetics 2019
58
15

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
15

BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer.
Azadeh Hajmirza, Anouk Emadali, Arnaud Gauthier, Olivier Casasnovas, Rémy Gressin, Mary B Callanan. Biomedicines 2018
87
15


Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016
372
15

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012
999
15

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
15

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.
Zhiyuan Yang, Jasper H N Yik, Ruichuan Chen, Nanhai He, Moon Kyoo Jang, Keiko Ozato, Qiang Zhou. Mol Cell 2005
801
13

BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.
Ballachanda N Devaiah, Brian A Lewis, Natasha Cherman, Michael C Hewitt, Brian K Albrecht, Pamela G Robey, Keiko Ozato, Robert J Sims, Dinah S Singer. Proc Natl Acad Sci U S A 2012
251
13

Structure and ligand of a histone acetyltransferase bromodomain.
C Dhalluin, J E Carlson, L Zeng, C He, A K Aggarwal, M M Zhou. Nature 1999
13

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
13

Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes.
Janine M Lamonica, Wulan Deng, Stephan Kadauke, Amy E Campbell, Roland Gamsjaeger, Hongxin Wang, Yong Cheng, Andrew N Billin, Ross C Hardison, Joel P Mackay,[...]. Proc Natl Acad Sci U S A 2011
160
13

Apabetalone downregulates factors and pathways associated with vascular calcification.
Dean Gilham, Laura M Tsujikawa, Christopher D Sarsons, Christopher Halliday, Sylwia Wasiak, Stephanie C Stotz, Ravi Jahagirdar, Michael Sweeney, Jan O Johansson, Norman C W Wong,[...]. Atherosclerosis 2019
40
15

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni,[...]. Clin Cancer Res 2015
186
13

BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.
Kalung Cheung, Geming Lu, Rajal Sharma, Adam Vincek, Ruihua Zhang, Alexander N Plotnikov, Fan Zhang, Qiang Zhang, Ying Ju, Yuan Hu,[...]. Proc Natl Acad Sci U S A 2017
65
13

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.
Shwu-Yuan Wu, A-Young Lee, Hsien-Tsung Lai, Hong Zhang, Cheng-Ming Chiang. Mol Cell 2013
217
13

Opposing Functions of BRD4 Isoforms in Breast Cancer.
Shwu-Yuan Wu, Chien-Fei Lee, Hsien-Tsung Lai, Cheng-Tai Yu, Ji-Eun Lee, Hao Zuo, Sophia Y Tsai, Ming-Jer Tsai, Kai Ge, Yihong Wan,[...]. Mol Cell 2020
48
13


Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Talal Khan, Neil Senzer, John Nemunaitis. Future Sci OA 2019
159
13

BET bromodomains as novel epigenetic targets for brain health and disease.
Mandakini B Singh, Gregory C Sartor. Neuropharmacology 2020
21
28

Cooperative binding of two acetylation marks on a histone tail by a single bromodomain.
Jeanne Morinière, Sophie Rousseaux, Ulrich Steuerwald, Montserrat Soler-López, Sandrine Curtet, Anne-Laure Vitte, Jérôme Govin, Jonathan Gaucher, Karin Sadoul, Darren J Hart,[...]. Nature 2009
309
13

Achieving clinical success with BET inhibitors as anti-cancer agents.
Tatiana Shorstova, William D Foulkes, Michael Witcher. Br J Cancer 2021
63
13

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Keith F McDaniel, Le Wang, Todd Soltwedel, Steven D Fidanze, Lisa A Hasvold, Dachun Liu, Robert A Mantei, John K Pratt, George S Sheppard, Mai H Bui,[...]. J Med Chem 2017
77
13

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Kevin G McLure, Emily M Gesner, Laura Tsujikawa, Olesya A Kharenko, Sarah Attwell, Eric Campeau, Sylwia Wasiak, Adam Stein, Andre White, Eric Fontano,[...]. PLoS One 2013
139
11

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
Olivier Mirguet, Romain Gosmini, Jérôme Toum, Catherine A Clément, Mélanie Barnathan, Jean-Marie Brusq, Jacqueline E Mordaunt, Richard M Grimes, Miriam Crowe, Olivier Pineau,[...]. J Med Chem 2013
208
11

Clinical trials for BET inhibitors run ahead of the science.
Guillaume Andrieu, Anna C Belkina, Gerald V Denis. Drug Discov Today Technol 2016
158
11

Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines.
Gerald V Denis, Mark E McComb, Douglas V Faller, Anupama Sinha, Paul B Romesser, Catherine E Costello. J Proteome Res 2006
106
11

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016
283
11

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Xiangpeng Dai, Wenjian Gan, Xiaoning Li, Shangqian Wang, Wei Zhang, Ling Huang, Shengwu Liu, Qing Zhong, Jianping Guo, Jinfang Zhang,[...]. Nat Med 2017
169
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.